Fast Melt Tablets Market Forecast and CAGR:
According to the latest research by Fact.MR, the fast melt tablets market is set to observer a growth of 9-10% during the forecast period. Demand for fast melt tablets expects to observer stable recovery in the short-term, with a positive growth position in the long run. High adoption of fast melt tablets technology will offer lucrative opportunities in near future.
Request For Sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=7045
Key Segments:
-
By Drug Class:
- Anti-Psychotics
- Anti-Epileptics
- CNS Stimulants
- Anxiolytics
- Anti-Parkinsonian Drugs
- Anti-Hypertensive
- NSAIDS
- Anti-Allergy Drugs
- Proton Pump Inhibitors
- Others
-
By Indication
- CNS Diseases
- GI Diseases
- CVS Disorders
- Allergy
- Others
-
By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By region:
- North America:
- Latin America
- Europe:
- East Asia:
- South Asia:
- Oceania:
- Middle East and Africa
Request For Customization – https://www.factmr.com/connectus/sample?flag=RC&rep_id=7045
Who are the key players in the Fast Melt Tablets Market?
Some of the manufacturers of fast melt tablet are
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AstraZeneca
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Eli Lily and Company
- Dr. Reddy’s Laboratories Ltd.
- Takeda Pharmaceutical Company Limited
- Kissei Pharmaceutical Co.Ltd.
For instance in June 2019, Kissei Pharmaceutical Co., Ltd. launched GLUBES® which is the new orally disintegrating dosage form of GLUBES® Combination Tab.
High adoption of fast-melt tablet by geriatric population give demand progress for fast melt tablets market during the forecast period. First pass metabolism is big issue in a conventional oral formulation that can be prevented with the help of fast melt tablet.
These drug delivery systems are capable of achieving patient compliance a great extent which boosts the demand. Self-administration is possible with high bioavailability and immediate action and decreased side effect of drug to patients. This are the formulation driving force for more adoption.
However, some technological challenges that may create hindrance in this drug delivery system can be the overcome with extensive research in formulation and development. This add on to more adoption of this fast-melt tablet.
Read More Trending Reports of Fact.MR- https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/
Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:
Fluoro Enzymatic Assays Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031
Shower Chairs Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031
Infrared Thermometer Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031
About Us:
Fact.MR research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
